Loading
Genetic Syndromes and Imprinting / Pancreatic Function and Diabetes · Journal article
Medicine · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of an adult woman with Prader–Willi syndrome and refractory type 2 diabetes mellitus who showed clinical improvement after substitution of a GLP-1 receptor agonist with the dual GIP/GLP-1 receptor agonist tirzepatide. The report raises a hypothesis about tirzepatide's potential utility in PWS-associated metabolic dysfunction but provides no quantified efficacy measures, comparator data, or evidence of generalizability.
Case report. Single adult female patient with genetically confirmed Prader–Willi syndrome and type 2 diabetes mellitus presenting with long-term poorly controlled blood glucose, hyperphagia, and morbid obesity.. Intervention: Tirzepatide (dual GIP/GLP-1 receptor agonist) substituted for prior GLP-1 receptor agonist within multidrug regimen..
Patient diagnosed with PWS in adulthood via heterozygous deletion in 15q11.2–q13.1 region and DNA methylation analysis Initial combination therapy with insulin, metformin, chiglitazar sodium, GLP-1 receptor agonist, and SGLT-2 inhibitor showed limited efficacy Substitution of GLP-1 receptor agonist with tirzepatide led to notable improvements in appetite suppression, body weight reduction, and glycemic control
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case suggests tirzepatide may merit consideration in PWS patients with refractory diabetes and severe hyperphagia, but the finding is anecdotal and cannot guide practice without controlled evidence. Clinicians should not generalize this single response to the broader PWS population.
A single case report describing clinical response to tirzepatide in an adult with Prader–Willi syndrome and refractory diabetes; lacks comparison group, quantified outcomes, and generalizability.
As stated by the source record.
This case suggests tirzepatide may merit consideration in PWS patients with refractory diabetes and severe hyperphagia, but the finding is anecdotal and cannot guide practice without controlled evidence. Clinicians should not generalize this single response to the broader PWS population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Rationale: Prader–Willi syndrome (PWS) is a complex genetic disorder that affects multiple systems and results from loss of expression of paternally inherited genes in the 15q11.2–q13 region. It is characterized by severe hypotonia and feeding difficulties during infancy, followed by hyperphagia in later childhood and adolescence, which, without strict control of excessive eating behaviors, ultimately leads to severe obesity associated with type 2 diabetes mellitus. Patient concerns: We present the case of a woman who was diagnosed with PWS and diabetes mellitus in adulthood. She had a history of hypotonia, developmental delay, intellectual disability, hyperphagia, and morbid obesity since childhood, with gonadal dysplasia emerging during puberty. She presented with long-term poorly controlled blood glucose levels. Diagnoses: Genetic testing revealed a heterozygous deletion in the 15q11.2–q13.1 region on chromosome 15, and DNA methylation analysis confirmed the diagnosis of PWS. Interventions: The distinctiveness of this case lies in the patient’s uncontrollable food-seeking behavior combined with PWS-related severe insulin resistance and β-cell dysfunction, which together resulted in refractory diabetes. Initial combination therapy using multiple glucose-lowering agents, including insulin, metformin, chiglitazar sodium, a glucagon-like peptide-1 receptor agonist, and a sodium-glucose cotransporter-2 inhibitor, demonstrated limited efficacy. Outcomes: Subsequent substitution of the glucagon-like peptide-1 receptor agonist with the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide led to notable improvements in appetite suppression, body weight reduction, and glycemic control. Lessons: This case underscores the importance of considering genetic syndromes in patients with diabetes presenting with early-onset severe obesity and developmental abnormalities and emphasizes the potential therapeutic value of novel antidiabetic agents such as tirzepatide for managing PWS-associated metabolic disturbances. These findings provide important insights into the diagnosis and treatment of diabetes complicated by PWS.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.